Association of biological antirheumatic therapy with risk for type 2 diabetes : a retrospective cohort study in incident rheumatoid arthritis
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To explore possible associations of treatment with biological disease-modifying antirheumatic drugs (bDMARDs), including T-cell-based and interleukin-6 inhibition (IL-6i)-based therapies, and the risk for type 2 diabetes mellitus (T2DM) in patients with rheumatoid arthritis (RA).
STUDY DESIGN, SETTING AND PARTICIPANTS: Five treatment groups were selected from a United States Electronic Medical Records database of 283 756 patients with RA (mean follow-up, 5 years): never received bDMARD (No bDMARD, n=125 337), tumour necrosis factor inhibitors (TNFi, n=34 873), IL-6i (n=1884), T-cell inhibitors (n=5935) and IL-6i+T cell inhibitor abatacept (n=1213). Probability and risk for T2DM were estimated with adjustment for relevant confounders.
RESULTS: In the cohort of 169 242 patients with a mean 4.5 years of follow-up and a mean 641 200 person years of follow-up, the adjusted probability of developing T2DM was significantly lower in the IL-6i (probability, 1%; 95% CI 0.6 to 2.0), T-cell inhibitor (probability, 3%; 95% CI 2.3 to 3.3) and IL-6i+T cell inhibitor (probability, 2%; 95% CI 0.1 to 2.9) groups than in the No bDMARD (probability, 5%; 95% CI 4.6 to 4.9) and TNFi (probability, 4%; 95% CI 3.7 to 4.7) groups. Compared with No bDMARD, the IL-6i and IL-6i+T cell inhibitor groups had 37% (95% CI of HR 0.42 to 0.96) and 34% (95% CI of HR 0.46 to 0.93) significantly lower risk for T2DM, respectively; there was no significant difference in risk in the TNFi (HR 0.99; 95% CI 0.93 to 1.06) and T-cell inhibitor (HR 0.96; 95% CI 0.82 to 1.12) groups.
CONCLUSIONS: Treatment with IL-6i, with or without T-cell inhibitors, was associated with reduced risk for T2DM compared with TNFi or No bDMARDs; a less pronounced association was observed for the T-cell inhibitor abatacept.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
BMJ open - 11(2021), 6 vom: 16. Juni, Seite e042246 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Paul, Sanjoy K [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antirheumatic Agents |
---|
Anmerkungen: |
Date Completed 18.06.2021 Date Revised 02.07.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/bmjopen-2020-042246 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM326826270 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM326826270 | ||
003 | DE-627 | ||
005 | 20231226203154.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/bmjopen-2020-042246 |2 doi | |
028 | 5 | 2 | |a pubmed24n1089.xml |
035 | |a (DE-627)NLM326826270 | ||
035 | |a (NLM)34135030 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Paul, Sanjoy K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association of biological antirheumatic therapy with risk for type 2 diabetes |b a retrospective cohort study in incident rheumatoid arthritis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.06.2021 | ||
500 | |a Date Revised 02.07.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVE: To explore possible associations of treatment with biological disease-modifying antirheumatic drugs (bDMARDs), including T-cell-based and interleukin-6 inhibition (IL-6i)-based therapies, and the risk for type 2 diabetes mellitus (T2DM) in patients with rheumatoid arthritis (RA) | ||
520 | |a STUDY DESIGN, SETTING AND PARTICIPANTS: Five treatment groups were selected from a United States Electronic Medical Records database of 283 756 patients with RA (mean follow-up, 5 years): never received bDMARD (No bDMARD, n=125 337), tumour necrosis factor inhibitors (TNFi, n=34 873), IL-6i (n=1884), T-cell inhibitors (n=5935) and IL-6i+T cell inhibitor abatacept (n=1213). Probability and risk for T2DM were estimated with adjustment for relevant confounders | ||
520 | |a RESULTS: In the cohort of 169 242 patients with a mean 4.5 years of follow-up and a mean 641 200 person years of follow-up, the adjusted probability of developing T2DM was significantly lower in the IL-6i (probability, 1%; 95% CI 0.6 to 2.0), T-cell inhibitor (probability, 3%; 95% CI 2.3 to 3.3) and IL-6i+T cell inhibitor (probability, 2%; 95% CI 0.1 to 2.9) groups than in the No bDMARD (probability, 5%; 95% CI 4.6 to 4.9) and TNFi (probability, 4%; 95% CI 3.7 to 4.7) groups. Compared with No bDMARD, the IL-6i and IL-6i+T cell inhibitor groups had 37% (95% CI of HR 0.42 to 0.96) and 34% (95% CI of HR 0.46 to 0.93) significantly lower risk for T2DM, respectively; there was no significant difference in risk in the TNFi (HR 0.99; 95% CI 0.93 to 1.06) and T-cell inhibitor (HR 0.96; 95% CI 0.82 to 1.12) groups | ||
520 | |a CONCLUSIONS: Treatment with IL-6i, with or without T-cell inhibitors, was associated with reduced risk for T2DM compared with TNFi or No bDMARDs; a less pronounced association was observed for the T-cell inhibitor abatacept | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a epidemiology | |
650 | 4 | |a rheumatology | |
650 | 4 | |a therapeutics | |
650 | 7 | |a Antirheumatic Agents |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
700 | 1 | |a Montvida, Olga |e verfasserin |4 aut | |
700 | 1 | |a Best, Jennie H |e verfasserin |4 aut | |
700 | 1 | |a Gale, Sara |e verfasserin |4 aut | |
700 | 1 | |a Pethö-Schramm, Attila |e verfasserin |4 aut | |
700 | 1 | |a Sarsour, Khaled |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 11(2021), 6 vom: 16. Juni, Seite e042246 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2021 |g number:6 |g day:16 |g month:06 |g pages:e042246 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2020-042246 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2021 |e 6 |b 16 |c 06 |h e042246 |